

# Pfizer Announces Successful Consent Solicitation Results For Three Series Of Debt

Thursday, August 23, 2012 - 11:15pm

## Extends Consent Solicitation for Two Smaller Series

--([BUSINESS WIRE](#))--Pfizer Inc. (NYSE: PFE) today announced the results of its solicitation of consents to amend certain provisions of the indentures with respect to the following outstanding debt securities of its wholly-owned subsidiary Pharmacia Corporation:

Debt Security	CUSIP No.	Outstanding Principal Amount
6.50% Debentures due 2018	71713UAQ5	\$461,550,000
6.75% Debentures due 2027	71713UAT9	\$200,000,000
6.60% Debentures due 2028	71713UAW2	\$658,985,000

Based on information provided by D.F. King & Co., Inc., the information and tabulation agent for the consent solicitation, as of 5:00 p.m., New York City time, on Thursday, August 23, 2012, the required consents from holders of the 6.50% Debentures due 2018, 6.75% Debentures due 2027 and 6.60% Debentures due 2028 had been received, and such consents had not been validly revoked prior to such expiration time. Adoption of the proposed amendments required consent of holders of at least a majority (greater than 50%) in principal amount of the outstanding 6.50% Debentures due 2018 and 6.60% Debentures due 2028 and of holders of at least 66 2/3% in principal amount of the outstanding 6.75% Debentures due 2027.

Pfizer expects to make the aggregate consent payment of approximately \$3.0 million to consenting holders on or about August 24, 2012 in accordance with the terms of the consent solicitation.

Pfizer also announced today the extension of the expiration time for the consent solicitation from 5:00 p.m., New York City time, on Thursday, August 23, 2012, to 5:00 p.m., New York City time, on Monday, August 27, 2012 with respect to the \$20,000,000 outstanding aggregate principal amount of 6.47% Notes due 2018, CUSIP No. 61167HBK8, and outstanding aggregate principal amount of \$2,507,000 8.70% Debentures due 2021, CUSIP No. 71713UAR3.

**Pfizer Inc: Working together for a healthier world™**

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of

medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at [www.pfizer.com](http://www.pfizer.com).

Pfizer Inc. Media Contact: Joan Campion, 212-733-2798 or Investor Contact: Suzanne Harnett, 212-733-8009